Barr Launches New Seasonale Ad, Increases Emphasis On Safety Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
The third version of Barr’s television ad responds to issues previously objected to by FDA’s ad division.
You may also be interested in...
Barr Scraps Seasonale Ad Revisions, Starts On New DTC Campaign
The company attributes a slowdown in growth for the extended-regimen oral contraceptive to the hiatus in direct-to-consumer advertising. The DTC spots were pulled after FDA objected to the original ad and the revised version. New ads will debut in late spring or early summer, CEO Downey says.
FDA Cites Barr Seasonale TV Ad For Misleading Risk Information
The direct-to-consumer ad fails to reveal that patients may experience breakthrough bleeding or spotting for up to a year, an FDA ad division letter states. The agency also says the risk information contained in the ad is obscured by the "compelling visuals."
Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says